Teriparatide

Teriparatide is a lab-made version of the active portion of human parathyroid hormone (PTH), consisting of amino acids 1 through 34. It is a bone anabolic agent, meaning it stimulates new bone formation rather than only slowing bone breakdown Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. The strongest evidence comes from osteoporosis trials, but research also examines fracture healing, spinal fusion, and medication-related jaw problems Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis+3. Teriparatide was the first approved osteoporosis drug that builds bone, approved in the early 2000s Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis.

Teriparatide activates the parathyroid hormone type 1 receptor (PTH1R), found on osteoblasts, the cells that build bone Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis+1. When given as a once-daily brief pulse, it triggers signaling that increases osteoblast number and activity, producing net bone formation Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. Continuous exposure to parathyroid hormone can instead favor bone breakdown, so the intermittent schedule is important Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis.

Secondary actions

• Bone cell differentiation: PTH1R signaling upregulates Runx2 and osterix, transcription factors that drive osteoblast development Teriparatide (1‐34 human PTH) regulation of osterix during fracture repair.
• Osteocyte requirement: Bone cells called osteocytes must have PTH1R for the bone-mass and strength gains, based on mouse studies DMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor.
• Local chemokine: Osteoblast-derived MCP1 (CCL2) rises shortly after PTH and appears necessary for the anabolic effect Anabolic effect of parathyroid hormone (1-34) to prevent ovariectomy induced bone loss is attenuated in Col1A1-cre floxed monocyte chemotactic protein 1 (MCP1, CCL2) mice.
• Renal calcium handling: PTH1R activation in the kidney increases active vitamin D synthesis and calcium reabsorption, producing a transient rise in serum calcium after dosing Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis+1.
• Cartilage effects: Preclinical work shows PTH(1-34) can suppress cartilage hypertrophy and improve matrix synthesis, which is why osteoarthritis is studied Potential effects of teriparatide (PTH (1–34)) on osteoarthritis: a systematic review+1.
• Osteocyte survival: PTH can induce autophagy in osteocytes, protecting them from glucocorticoid damage in cell studies Parathyroid Hormone (PTH) Induces Autophagy to Protect Osteocyte Cell Survival from Dexamethasone Damage.

Bone mineral density and fracture

In postmenopausal osteoporosis trials, 20 mcg once daily increased lumbar spine bone mineral density by about 9.7% and hip bone mineral density by 2.6% over 18 months Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. That study reported a 65% relative reduction in vertebral fractures and 35% for appendicular fractures Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. Teriparatide also outperformed several antiresorptives for lumbar spine bone mineral density in glucocorticoid-induced osteoporosis Effectiveness of Anti-Osteoporotic Medications in the Management of Glucocorticoid-Induced Osteoporosis: A Systematic Review and Network Meta-Analysis on Behalf of the ECTS Clinical Action Group.

Bone healing and surgery

A prospective delayed-union study reported radiologic union in 81.2% of adults at 12 weeks with 20 mcg daily Teriparatide as an Adjunct in Managing Delayed Union of Long Bone Fractures: Insights from a Tertiary Care Center. In a retrospective tibial shaft nonunion study, teriparatide plus reamed nailing healed faster than nailing alone Biological Augmentation of Reamed Intramedullary Nailing for Aseptic Tibial Shaft Nonunion: An Exploratory Multicenter Retrospective Comparative Cohort Study. However, a randomized trial in proximal humerus fractures found no significant improvement in callus, pain, or function with a 4-week course PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures.

Spine, jaw, and other

Perioperative teriparatide in spinal fusion was associated with lower risk of proximal junctional kyphosis and radiographic nonunion Association of Perioperative Teriparatide Use with Postoperative Complications in Spinal Fusion Surgery: A Systematic Review and Meta-Analysis. In medication-related osteonecrosis of the jaw, a meta-analysis favored teriparatide for improvement in staging Should Teriparatide Be Part of Our Clinical Armamentarium in the Management of Medication-Related Osteonecrosis of the Jaw? A Systematic Review and Meta-Analysis. Preclinical osteoarthritis models show slowed progression, but human data are absent Potential effects of teriparatide (PTH (1–34)) on osteoarthritis: a systematic review.

Research protocols commonly use teriparatide at 20 mcg once daily by subcutaneous injection, across osteoporosis, delayed union, and spinal fusion studies Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis+2. The same fixed dose is used regardless of body weight in adult osteoporosis trials Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis.

Representative protocols

The once-daily schedule is dominant in the evidence base. Twice-daily dosing appears only in severe hypocalcemia case reports, not routine osteoporosis Transient teriparatide for postoperative hypocalcaemia with hungry bone features. Community protocols for general healing often use 20 mcg daily for 3-6 months, but this is less formalized.

Lyophilized teriparatide powder is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol), which is preferred for multi-dose handling. Sterile water may be used if sterility can be maintained. The diluent should be added gently, and the vial swirled rather than shaken, to avoid denaturing the peptide. Lyophilized teriparatide should be stored frozen for long term, with refrigeration acceptable for weeks to months. Reconstituted teriparatide must be refrigerated and protected from light, and it should not be frozen. It degrades by time- and temperature-dependent pathways, and a breakdown product, PTH 1-33, has been detected after dosing Sub‐picomolar quantification of PTH 1‐34 in plasma by UHPLC‐MS/MS after subcutaneous injection of teriparatide and identification of PTH 1‐33, its degradation product+1. Biosimilar teriparatide has demonstrated physicochemical similarity to the reference product, supporting consistent handling expectations Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product. Refer to the calculator below for specific diluent volumes and dose volumes.

Antiresorptives

Prior bisphosphonate exposure is associated with a smaller lumbar spine bone mineral density response to teriparatide, by an average of about 2.2 percentage points, with no significant difference at the hip Influence of bisphosphonate pretreatment on bone mineral density gains and fracture outcomes with teriparatide: A systematic review and meta-analysis. Starting teriparatide after bisphosphonates still produces meaningful gains, but the spine response may be smaller. Combining zoledronic acid with teriparatide showed greater bone mineral density gains than either therapy alone in postmenopausal osteoporosis Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. In osteogenesis imperfecta, sequential teriparatide followed by zoledronic acid improved bone mineral density but did not reduce fractures Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

Denosumab

Overlapping denosumab with teriparatide improved the vertebral bone marrow microenvironment and lumbar spine bone mineral density more than sequential switching in a propensity-matched study Effect of combination versus sequential teriparatide initiation on vertebral bone marrow microenvironment in postmenopausal women with prior denosumab treatment: A propensity score-matched study. Abrupt denosumab cessation can cause rebound fractures, so clinical guidance emphasizes avoiding a hard stop when transitioning Discontinuing Long-Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?.

Calcium, vitamin D, and other drugs

Teriparatide causes a transient serum calcium rise, peaking around 4 hours after a dose and resolving by 16-24 hours Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis. Pharmacovigilance data rank teriparatide among the most frequently reported drugs associated with hypercalcemia Pharmacovigilance insights into drug-induced hypercalcemia: evidence from the U.S. FDA Adverse Event Reporting System (FAERS) database. Combining with thiazide diuretics or digoxin carries theoretical concerns because hypercalcemia can affect digoxin toxicity, but no direct interaction trials are provided. In hypoparathyroidism, calcium and active vitamin D doses usually need reduction when teriparatide is added to avoid hypercalcemia Teriparatide Therapy in Children with Hypoparathyroidism: A Systematic Review and Meta-Analysis. Strontium potentiated teriparatide anabolic effects in ovariectomized rats, but no human data exist Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats.

Teriparatide is most commonly studied in combination with antiresorptive agents rather than with other peptides. Combining teriparatide with zoledronic acid produced greater bone mineral density gains than monotherapy in postmenopausal osteoporosis Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. Overlapping denosumab with teriparatide improved vertebral bone quality and lumbar spine bone mineral density compared with a sequential switch Effect of combination versus sequential teriparatide initiation on vertebral bone marrow microenvironment in postmenopausal women with prior denosumab treatment: A propensity score-matched study. The typical sequence in research protocols is anabolic therapy first, followed by an antiresorptive to preserve the bone gained; only about 25% of patients in one U.S. cohort had timely antiresorptive consolidation Timeliness of antiresorptive consolidation after anabolic therapy for primary fracture prevention: A US cohort study. No controlled human trials have tested stacking teriparatide with healing peptides such as BPC-157 or TB-500, so any additive benefit is unproven.

Teriparatide is FDA approved for postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis, and glucocorticoid-induced osteoporosis Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. A biosimilar, Terrosa, was approved in the EU in 2017 Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product. The FDA separately approved palopegteriparatide (Yorvipath) for hypoparathyroidism in adults, while teriparatide itself remains off-label for hypoparathyroidism Palopegteriparatide (Yorvipath) for hypoparathyroidism. Uses in fracture healing, medication-related osteonecrosis of the jaw, and pediatric osteogenesis imperfecta are off-label Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis+2. No source in the provided corpus identifies a controlled-substance schedule or WADA anti-doping classification for teriparatide.

Common effects

In trials, nausea, headache, dizziness, and leg cramps are the most common adverse events Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. Serum calcium rises transiently after a dose, peaking around 4 hours and returning to baseline by 16-24 hours Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis. Persistent hypercalcemia is rare at the standard 20 mcg dose, but teriparatide appears frequently in hypercalcemia reports submitted to the U.S. FDA Pharmacovigilance insights into drug-induced hypercalcemia: evidence from the U.S. FDA Adverse Event Reporting System (FAERS) database.

Uncommon and rare risks

Hypercalcemia requiring dose reduction occurred in 3% and discontinuation in 0.2% in the pivotal trial Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. Rare case reports describe nonuremic calciphylaxis and cutaneous vascular calcification, often in people with kidney dysfunction, warfarin use, or glucocorticoid exposure Cutaneous Vascular Calcifications Secondary to Treatment with Teriparatide+1. High-dose rat studies showed osteosarcoma, but no osteosarcoma cases were reported among about 2,800 trial patients Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis+1. This underlies a 24-month lifetime treatment limit in prescribing guidance.

Contraindications and monitoring

The regulatory label lists hypercalcemia, history of osteosarcoma, Paget's disease, prior skeletal radiation, and open epiphyses as contraindications Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of Osteoporosis. Monitoring typically includes serum calcium, creatinine, and sometimes 24-hour urine calcium, especially in people with kidney impairment or hypoparathyroidism Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis+1.